These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 21972730)
1. [Current management of myelodysplastic syndromes]. Caers J; Bonnet C; Graux C; De Prijck B; Beguin Y Rev Med Suisse; 2011 Aug; 7(306):1634, 1636-8, 1640-3. PubMed ID: 21972730 [TBL] [Abstract][Full Text] [Related]
2. Novel agents for the management of myelodysplastic syndromes. Meletis J; Viniou N; Terpos E Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944 [TBL] [Abstract][Full Text] [Related]
3. [Current management of myelodysplastic syndromes]. Vey N; Charbonnier A Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543 [TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in myelodysplastic syndromes. Atallah E; Garcia-Manero G Cancer Invest; 2008 Mar; 26(2):208-16. PubMed ID: 18259954 [TBL] [Abstract][Full Text] [Related]
5. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S; Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903 [TBL] [Abstract][Full Text] [Related]
6. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676 [TBL] [Abstract][Full Text] [Related]
7. [Management of myelodysplastic syndromes]. Duchmann M; Fenaux P; Cluzeau T Bull Cancer; 2015 Nov; 102(11):946-57. PubMed ID: 26410692 [TBL] [Abstract][Full Text] [Related]
8. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673 [TBL] [Abstract][Full Text] [Related]
9. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
11. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Stahl M; Zeidan AM Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851 [TBL] [Abstract][Full Text] [Related]
12. How we manage adults with myelodysplastic syndrome. Fenaux P; Platzbecker U; Ades L Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328 [TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Barzi A; Sekeres MA Cleve Clin J Med; 2010 Jan; 77(1):37-44. PubMed ID: 20048028 [TBL] [Abstract][Full Text] [Related]
15. The evolution of hematopoietic SCT in myelodysplastic syndrome. Kindwall-Keller T; Isola LM Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532 [TBL] [Abstract][Full Text] [Related]